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Summary.-A randomized trial comparing routine follow-up with a treatment regi-
men aimed at increasing specific anti-tumour immunity has been carried out in 95
patients after total surgical excision of lung cancer (not small-cell). Treatment con-
sisted of inoculation with an autologous irradiated suspension of tumour cells
combined with a small dose of C. parvum given intradermally during convalescence.
Although treatment was associated with virtually no side effects, there has been no
apparent benefit and input to the trial has now stopped.
WHILE surgical excision remains the
cornerstone in the management ofpotenti-
ally curable cases of lung cancer, it is
depressing to note that this most favour-
able group of patients has a 5-year sur-
vival rate of 25-30% (Stott et al., 1976).
These patients, suffering from what is
considered to be early cancer (i.e. localized
to the lung or at most involving the drain-
ing lymph nodes) commonly harbour more
extensive disease than is revealed by
surgery. Indeed a survey of post mortems
on these patients dying of post-operative
complications within a month ofoperation
revealed that 35%0 harboured residual
disease (local plus metastatic) (Mathews
et al., 1973). Some form of additional
treatment therefore seems justified.
Chemotherapeutic agents which appear
to be active against advanced lung cancer
can cause considerable long and short-
term toxicity. These drugs may also be
unacceptable to most patients when used
in this post-surgical adjuvant role. They
can also cause increased morbidity especi-
ally when many of these patients are in
poor general health. Nor is there any clear
evidence that this approach improves
survival (Stott et al., 1976).
Post-operative empyema may improve
the prognosis after surgery in lung cancer
(Ruckdeschel et al., 1972). When this
action was mimicked using post-operative
intrapleural BCG, a similar improvement
in prognosis was found, though only in
patients with Stage I disease (McKneally
et al., 1976). Sinus hyperplasia in the
draining lymph nodes (Black & Speer,
1958) and active macrophages around the
primary tumour (Stewart, 1969) appar-
ently indicate a favourable prognosis, and
may suggest that the patient's immune
system has recognized a tumour-specific
antigen and is reacting against it. On the
other hand, depression of cell-mediated
immunity in advanced malignant disease
is both common and of poor prognostic
significance (Baldwin et al., 1973; Israel
et al., 1973).
The combination ofi.d. or s.c. injections
of mixtures of irradiated tumour cells and
C. parvum (CP) has been shown to sup-
press tumour development in a number of
animal models. For example, small doses
of CP have been combined with s.c. injec-
tions of irradiated mouse mastocytoma
cells by Stott (1975) and i.d. injections of
irradiated mouse fibrosarcoma cells by
Bomford (1975). Both workers reported
that this form of treatment produced a
strong specific cell-mediated immunity.
Surgical excision of the primary tumourSTUDY ON BRONCHIAL ANTIGENS
followed by treatment with CP and
irradiated tumour cells has been studied in
a rat hepatoma model. When treatment
was given after excision of the primary
tumour there was a reduction in the de-
velopment and number oflung metastases
(Procter et al., 1973).
Even in these animal models the timing
of treatment, the route of administration
and the respective doses of tumour cells
and CP was critical. Indeed Woodruff has
highlighted the need for caution in clinical
trials based on this animal work and urged
that only small doses of CP be used in
combined treatment, since large doses
may enhance tumour development.
A clinical trial was planned using
autologous irradiated lung-cancer cells,
which were re-injected into the dermis of
the thigh, along with a very small dose of
CP during convalescence.
PATIENTS
Ninety-fivepatients withhistologically con-
firmed cancer ofthe lung were included in the
study. Randomization was carried our per-
operatively by the surgeon responsible for the
procedure, when he believed that all macro-
scopic tumour had been resected, and antici-
pated a relatively smooth post-operative
course. Randomization tables were used and
slips placed in sealed envelopes which were
opened in sequence. Allocation was to a no-
treatment arm, when routine follow-up alone
was carried out, or to treatment with autolo-
gous tumour cells. Patients were staged
subsequently after pathological analysis of
the resected specimens. Stage I patients were
those with tumour localized within the lung
and Stage II had involvement ofthe draining
nodes but no distant dissemination.
If a patient was randomized to treatment,
a sample of fresh tumour was taken immedi-
ately from theatre and a cellular suspension
prepared understerile conditions. Themethod
used was similar to that described by
Bomford (1975) and no enzymes like collagen-
ase were used to disaggregate the tumour.
Fine maceration of the tumour was followed
by several washes in Eagle's medium. The
final suspension was tested for cell viability
by exclusion of trypan blue, a count per-
formed and then stored, after controlled-rate
freezing, at - 1400C. Tumour cells were
recognized on morphological grounds and the
resulting suspensions contained 20-30%
tumour cells.
Treatment was given during convalescence,
14-28 days after surgery. On the day of
treatment a sample containing 20x 106
tumour cells was irradiated with 100 Gy and
30 pg of CP added with medium to a final
volume of 1.5 ml.
The trial was approved by the ethics com-
mittee of the Oxford Area Health Authority
and informed consent was obtained from all
patients randomized to immunotherapy.
C. parvum was obtained as a generous gift
from Dr T. J. Priestman of the Wellcome
Research Foundation, Beckenham, Kent.
RESULTS
A total of 95 patients have been in-
cluded in the trial, 49 in the control group
and 46 in the treatment group. In each
group the average age of the patients was
similar and patients were predominantly
male. Nine out of a total of 14 female
patients are in the control group.
TABLE I.-Overall death rate oflung cancer
patients following surgery according to
their allocation to treatment groups or not
Number
Deaths (%)
MIean time to
death (mths)
Treatment
46
20 (43 5)
12-5
Control
49
17 (35)
13*1
TREATED I
months
FIo. 1. Overall survival of all patients at
24 months.
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Ifall the patients randomised to therapy
are considered, then the treatment group
shows an apparently poorer survival, but
this is not significant (Table I, Fig. 1).
However, in this group, 12 patients did
not receive treatment; 6 patients were
either too unwell or died post-operatively;
2 did not attend the follow-up clinic on
the day of treatment; 2 were suspected of
harbouring residual disease on review, and
in 2 a satisfactory cell suspension could
not be prepared. Exclusion of the 6 treat-
ment-group and 3 control-group patients
who died within 3 months of operation,
shows very little difference in survival
between the two groups (Table II). When
TABLE II.-Death rateofpatients in TableI,
excluding those dying within 3 months of
surgery
Tireatn
Number 40
Deaths (%) 14 (3
Mean time to
death (mtlis) 17-3
nent Contirol
46
35) 14 (30)
15-6
only those patients who actually received
treatment are compared with the controls,
and the analysis performed from the usual
time of inoculation (1 month after opera-
tion) there is again no significant effect of
treatment (Table III).
TABLE III. Patients receiving immuno-
therapy vs controls; excluding any dying
within 1 month of surgery
Treatment ContrIol
Number 33 47
D)eaths (%) 11(33-3) 15 (31 9)
Mean time to
death (mths) 17 14-1
When the outcome is assessed according
to the stage oftumour spread at operation,
the expected poor results are seen after
surgery in patients with involvement of
the regional lymph nodes (Table IV, Fig.
2). Treatment does not appear to have
influenced the outcome in either Stage I
or II disease. It can be seen that 13/46 of
patients in the treatment group had
Stage II disease, compared with 11/49 in
TABLE IV.-Overall survival according to
tumour stage at operation
Stage I
Alive
Dead
Stage II
Alive
Dead
Treatment Control
21 27
12 (14-8)* 11 (16 8)
5
8 (9.1)
5
6 (6.2)
* Median survival time in months.
months
FIG. 2.-Survival accor(ling to stage at
operation.
TABLE V.-Histological type (and death
rate) of patients surviving 3 months
Squamous
Acdenocarcinoma
Undifferentiate(d
Large cell
Small cell
Treatment
33 (14)
3 (0)
Control
34 (9)
4 (0)
3 (0) 7 (5)
1 (0) 1 (0)
the control group. Eight of the 13 treat-
ment patients with Stage II tumours are
dead at a median time of 9 1 months after
operation. This compares with 6 of the 11
control patients with Stage II, who had a
median survival of only 6-2 months.
Table V shows that there was an even
distribution of histological types in the
two groups. Although it had been intended
to exclude patients with small-cell tumours
from this trial, 3 such tumours were diag-
nosed on the histology of the resected
specimens afterrandomization. These have
been included, and the 2 patients with
this histology in the treatment group were
given immunotherapy. The Table shows
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TABLE VI. Survivalaccording to operation
ofpatients living 3 months post-op
Pneumon-
Lobectomy ectomy
Me(lian Median
survival survival
No. (mtlis) No. (mths)
Treatment
Alive
Dea(d
Control
Aliv e
Dea(d
17
6
27
9
20-3
11 4
9
8
5
5
13-5
12 2
that treatment did not improve survival
in any histological type. It is ofinterest to
note that all 7 patients with a diagnosis of
adenocarcinoma who were alive at 3
months are still alive at a median time
from surgery of 23 months in the treat-
ment group and 15-5 months in the control
group.
Four out of 5 patients with anaplastic
cancer in the treatment group survived
longer than 3 months from surgery. All of
these are still alive at a median time of 10
months. In view of the small numbers
involved, however, no conclusions can be
drawn.
When survival is assessed according to
the nature of the operation (Table VI)
there is no significant difference in the
results. This analysis has been made on
patients surviving more than 3 months
after the operation and 17/40 (42.5o%) of
the treatment patients had a pneumon-
ectomy compared with only 10/46 (22%)
of the controls. It is apparent that the
patients randomized to immunotherapy
were suffering from rather more extensive
disease. This may explain more post-
operative deaths in the treatment group.
DISCUSSION
Attempts to increase anti-tumour im-
munity in human malignancies must be at
least partly empirical. The results of
laboratory experiments may be helpful
but not necessarily of direct clinical
relevance. While tumour-specific antigens
can be identified in artificially induced
malignancies in experimental animals
(Prehn & Main, 1957) this is not yet true
in human cancer. Although there is in-
direct evidence, both for the presence of
tumour-specific antigens and host immune
reactivity against these putative antigens,
the mechanisms of the host reponses to
cancer remain unclear.
It has been claimed that immuno-
therapy with allogeneic tumour cells and
BCG given i.d. after surgery for Stage II
malignant melanoma produced a 50%0
reduction in metastases, compared with
historical controls (Eilber et al., 1976). In
that study, one group of patients received
BCG by weekly i.d. injection, while
another group (15 patients) received the
same BCG treatment combined with 108
allogeneic melanoma cells weekly for 3
months. Both groups showed similar im-
provements in survival over historic con-
trols. However, a very similar trial in this
country, using concurrent control patients,
showed an alarming trend towards early
recurrence in the treatment group, and
the trial was brought to an early halt
(Mcllimurray et al., 1977). In this trial
only 8 patients were treated. This took the
form of an i.d. injection of live BCG and
autologous irradiated tumour cells admin-
istered at several sites on a single occasion.
Numerous trials ofimmunotherapy have
been reported in both early and late cases
of lung cancer. In many of these trials,
immune stimulation was combined with
either chemo- or radiotherapy, thus mak-
ing the results difficult to interpret
(Mikulski et al., 1979).
BCG, along with irradiated allogeneic
tumour cells has been given i.d. to patients
suffering from all stages of lung cancer.
The results have been compared with
groups receiving BCG alone or no addi-
tional treatment. There was no benefit
from treatment in advanced disease, but
patients with Stage I and II disease have
not yet been evaluated (Perlin et al., 1977).
The interpretation of the results of this
treatment was complicated in Stage III
patients as radiotherapy or chemotherapy
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were added as considered clinically indi-
cated.
Claims of benefit after surgery for
Stage III tumours have been made using
autologous tumour-cell vaccine treated
with Vibrio cholera neuramidase and Con-
canavalin A injected i.d. with Freund's
complete adjuvant. However, as the
treatment group of patients required less
extensive surgery and had a higher pro-
portion of patients with adenocarcinoma,
the interpretation of benefit is doubtful
(Takita et al., 1978).
A controlled randomized trial of intra-
pleural BCGr in surgically resected lung
cancer carried out in this country, failed
to confirm the experience of McNeally
(Lowe et al., 1980). The authors point out
various minor differences in the treatment
given, but it seems unlikely that these
were sufficient to explain the differences
in the results between the two trials.
By administering a cellular suspension
of autologous tumour cells which were
irradiated to prevent local implantation or
dissemination, and combined with a small
dose of CP, it was hoped to augment host
resistance to any residual lung tumour. By
injecting this vaccine in the thigh where it
would drain to lymph nodes unlikely to
have had previous exposure to the tumour
antigen, and by using CP for its adjuvant
effect (Howard et al., 1973) it was hoped
that these immunocompetent nodes might
produce specific anti-tumour reactivity.
Analysis of the results fails to show any
such benefit. It does not appear that there
havebeenanyadverseeffectsfromthistype
oftherapy, andside effects were minimal.
The overall results of immunotherapy
in lung cancer are not encouraging, and
we do not feel that any long-term benefit
is likely from the approach adopted in this
trial. It seems unlikely that this form of
treatment will become relevant until lung-
tumour-specific antigens are identified,
assuming that they exist. The recent ad-
vances using hybridoma-derived mono-
clonal antibodies suggest that this may
not be such a remote long-term aim
(Herlyn, 1979).
Thlis trial was supported by a grant from the
Cancer Research Campaign.
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